Azitra, Inc. (AZTR)
NYSEAMERICAN: AZTR · Real-Time Price · USD
0.6870
-0.0170 (-2.41%)
At close: Oct 17, 2025, 4:00 PM EDT
0.7050
+0.0180 (2.62%)
After-hours: Oct 17, 2025, 8:00 PM EDT
Azitra Revenue
In the year 2024, Azitra had annual revenue of $7.50K, down -98.91%.
Revenue (ttm)
$7.50K
Revenue Growth
-98.91%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
12
Market Cap
2.42M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 7.50K | -678.50K | -98.91% |
Dec 31, 2023 | 686.00K | 402.00K | 141.55% |
Dec 31, 2022 | 284.00K | 174.00K | 158.18% |
Dec 31, 2021 | 110.00K | -315.00K | -74.12% |
Dec 31, 2020 | 425.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 92.15B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
AZTR News
- 14 days ago - Azitra Receives Notice of Non-Compliance from NYSE American - PRNewsWire
- 6 weeks ago - Azitra, Inc. to Present at the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 7 weeks ago - Azitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated Rash - PRNewsWire
- 2 months ago - Stock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole—EpicQuest, Zoom, Azitra Stocks In Focus - Benzinga
- 2 months ago - Azitra, Inc. Announces Q2 2025 Results and Provides Business Updates - PRNewsWire
- 2 months ago - Azitra, Inc. Announces Reverse Stock Split - PRNewsWire
- 4 months ago - Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton Syndrome - PRNewsWire
- 4 months ago - Azitra, Inc. Announces Presentation at the 2025 BIO International Convention - PRNewsWire